Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 300

1.

Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis.

Ma L, Zhang X, Xiang Q, Zhou S, Zhao N, Xie Q, Zhao X, Zhou Y, Cui Y.

Basic Clin Pharmacol Toxicol. 2018 Aug 13. doi: 10.1111/bcpt.13111. [Epub ahead of print]

PMID:
30103286
2.

Biological Predictors of Clozapine Response: A Systematic Review.

Samanaite R, Gillespie A, Sendt KV, McQueen G, MacCabe JH, Egerton A.

Front Psychiatry. 2018 Jul 26;9:327. doi: 10.3389/fpsyt.2018.00327. eCollection 2018.

3.

Prevalence of polymorphisms in the ANKK1, DRD2, DRD3 genes and metabolic syndrome in refractory schizophrenia.

Pinto JAF, Freitas PHB, Nunes FDD, Granjeiro PA, Santos LLD, Machado RM.

Rev Lat Am Enfermagem. 2018;26:e2983. doi: 10.1590/1518-8345.2222.2983. Epub 2018 May 17. Portuguese, Spanish, English.

4.

[The effect of antipsychotic drug on monoamine receptors in peripheral blood mononuclear cells: affinity linked mechanism].

Taraskina AE, Zabotina AM, Nasyrova RF, Sosin DN, Sosina KA, Ershov EE, Grunina MN, Krupitsky EM.

Biomed Khim. 2018 Mar;64(2):201-207. doi: 10.18097/PBMC20186402201. Russian.

PMID:
29723151
5.

Association study of BDNF and DRD3 genes with alcohol use disorder in Schizophrenia.

Zai CC, Manchia M, Zai GC, Woo J, Tiwari AK, de Luca V, Kennedy JL.

Neurosci Lett. 2018 Apr 3;671:1-6. doi: 10.1016/j.neulet.2018.01.033. Epub 2018 Jan 31.

PMID:
29357295
6.

Potential link between genetic polymorphisms of catechol-O-methyltransferase and dopamine receptors and treatment efficacy of risperidone on schizophrenia.

Han J, Li Y, Wang X.

Neuropsychiatr Dis Treat. 2017 Dec 5;13:2935-2943. doi: 10.2147/NDT.S148824. eCollection 2017.

7.

No association between dopamine D3 receptor gene Ser9Gly polymorphism (rs6280) and risk of schizophrenia: an updated meta-analysis.

Qi XL, Xuan JF, Xing JX, Wang BJ, Yao J.

Neuropsychiatr Dis Treat. 2017 Nov 23;13:2855-2865. doi: 10.2147/NDT.S152784. eCollection 2017.

8.

cAMP levels in lymphocytes and CD4+ regulatory T-cell functions are affected by dopamine receptor gene polymorphisms.

Cosentino M, Kustrimovic N, Ferrari M, Rasini E, Marino F.

Immunology. 2018 Mar;153(3):337-341. doi: 10.1111/imm.12843. Epub 2017 Oct 16.

PMID:
28940477
9.

The effects of buspirone on occupancy of dopamine receptors and the rat gambling task.

Di Ciano P, Cormick PM, Stefan C, Wong E, Kim A, Remington G, Le Foll B.

Psychopharmacology (Berl). 2017 Nov;234(22):3309-3320. doi: 10.1007/s00213-017-4715-5. Epub 2017 Aug 19.

PMID:
28825117
10.

Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model.

Duric V, Banasr M, Franklin T, Lepack A, Adham N, Kiss B, Gyertyán I, Duman RS.

Int J Neuropsychopharmacol. 2017 Oct 1;20(10):788-796. doi: 10.1093/ijnp/pyx038.

11.

The impact of common dopamine D2 receptor gene polymorphisms on D2/3 receptor availability: C957T as a key determinant in putamen and ventral striatum.

Smith CT, Dang LC, Buckholtz JW, Tetreault AM, Cowan RL, Kessler RM, Zald DH.

Transl Psychiatry. 2017 Apr 11;7(4):e1091. doi: 10.1038/tp.2017.45.

12.

[Investigation of CNTF, COMT, DDR1, DISC1, DRD2, DRD3, and DTNBP1 candidate genes in schizophrenia: Results from the Hungarian SCHIZOBANK Consortium].

Benkovits J, Magyarosi S, Pulay AJ, Makkos Z, Egerhazi A, Balogh N, Almos P, Liko I, Schizobank Consortium H, Nemeth G, Molnar JM, Nagy L, Rethelyi JM.

Neuropsychopharmacol Hung. 2016 Dec;18(4):181-187. Hungarian.

13.

Effect on the expression of drd2 and drd3 after neonatal lesion in the lymphocytes, nucleus accumbens, hippocampus and prefrontal cortex: comparative analysis between juvenile and adult Wistar rats.

Genis-Mendoza AD, Tovilla-Zárate CA, López-Narvaez L, Mendoza-Lorenzo P, Ostrosky-Wegman P, Nicolini H, González-Castro TB, Hernández-Diaz Y.

Hereditas. 2016 Nov 22;153:13. doi: 10.1186/s41065-016-0018-9. eCollection 2016.

14.

Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain.

Purves-Tyson TD, Owens SJ, Rothmond DA, Halliday GM, Double KL, Stevens J, McCrossin T, Shannon Weickert C.

Transl Psychiatry. 2017 Jan 17;7(1):e1003. doi: 10.1038/tp.2016.257.

15.

Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.

Iwata Y, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Plitman E, Chung JK, Mar W, Gerretsen P, Pollock BG, Mulsant BH, Rajji TK, Mamo DC, Graff-Guerrero A.

J Clin Psychiatry. 2016 Dec;77(12):e1557-e1563. doi: 10.4088/JCP.15m10538.

PMID:
28086010
16.

Two Binding Geometries for Risperidone in Dopamine D3 Receptors: Insights on the Fast-Off Mechanism through Docking, Quantum Biochemistry, and Molecular Dynamics Simulations.

Zanatta G, Della Flora Nunes G, Bezerra EM, da Costa RF, Martins A, Caetano EW, Freire VN, Gottfried C.

ACS Chem Neurosci. 2016 Oct 19;7(10):1331-1347. Epub 2016 Aug 5.

PMID:
27434874
17.

Association study of dopamine receptor genes polymorphisms with the risk of schizophrenia in the Han Chinese population.

Yang B, Niu W, Chen S, Xu F, Li X, Wu X, Cao Y, Zhang R, Yang F, Wang L, Li W, Xu Y, He L, He G.

Psychiatry Res. 2016 Nov 30;245:361-364. doi: 10.1016/j.psychres.2016.08.052. Epub 2016 Aug 25.

PMID:
27591410
18.

Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.

Fervaha G, Caravaggio F, Mamo DC, Mulsant BH, Pollock BG, Nakajima S, Gerretsen P, Rajji TK, Mar W, Iwata Y, Plitman E, Chung JK, Remington G, Graff-Guerrero A.

Psychopharmacology (Berl). 2016 Oct;233(21-22):3803-3813. Epub 2016 Aug 24.

19.

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.

Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A.

Psychopharmacology (Berl). 2016 Oct;233(19-20):3503-12. doi: 10.1007/s00213-016-4382-y. Epub 2016 Aug 15.

20.

Current drug treatments targeting dopamine D3 receptor.

Leggio GM, Bucolo C, Platania CB, Salomone S, Drago F.

Pharmacol Ther. 2016 Sep;165:164-77. doi: 10.1016/j.pharmthera.2016.06.007. Epub 2016 Jun 22. Review.

PMID:
27343365

Supplemental Content

Loading ...
Support Center